Risk factors related to infections during the first year of highly active antiretroviral therapy;Factores de riesgo asociados a la aparición de infecciones durante el primer año de tratamiento antirretroviral de alta eficacia

Medicina Clinica

Volumn 116, Issue 2, 2001, Pages 41-46

  Amador, Concepción ^a   Bodi, Vicente ^a   Pasquau, Francisco ^a   Ena, Javier ^a   Benito, Concepción ^a   Fenoll, Vicenta ^a  

^a HOSPITAL MARINA BAIXA   (Spain)

Author keywords

Antiretroviral therapy; Nadir of CD4+; Opportunistic infections; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR;

ADULT; ARTICLE; COMMUNITY HOSPITAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; RISK FACTOR; TOXOPLASMOSIS; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0343408416     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71715-0     Document Type: Article

References (18)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Furher J, Satten GA et al. Declining morbility and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G et al. Impact of protease inhibitors on AIDS - defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1997; 11: F101-105.
3. García de Olalla P, Caylá JA, Brugal MT, Galdós H, Jansá JM, Clos R. Evolución de la mortalidad y supervivencia del sida en Barcelona (1981-1997). Med Clin (Barc) 1999; 113: 169-170.
4. Centers for Disease Control, 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: RR-17.
5. Powderly WG. Opportunistic infections and tumors [abstract PL 5.1]. Abstracts of the Fourth International Congress on Drug Therapy in HIV-Infection. Glasgow, Scotland, AIDS 1998; 12 (Supl 4): 5.
6. Maggiolo F, Bottura P, Caprioli S, Migliorino G, Marchetti G, Suter F. HIV-RNA serum levels correlate with CD4 T-Cell Counts [resumen 1-246]. Abstract from 38th annual interscience conference on Antimicrobial Agents and Chemotherapy. San Diego, California, 1998
7. Brettle RP, Wilson A, Povey V, Leen CSL, Huchinson S, Gore S. Combination therapy for HIV in a predominantly drug user cohort incidence of opporturistics events [abstract P 246]. Abstracts of the Fourth International Congress on Drug Therapy in HIV infection, Glasgow, Scotland, AIDS 1998; 12 (Supl 4): 85.
8. Garcia Vázquez E, De Gorgolas Hernández M, Garcia Delgado R, Fernández Guerrero ML. Suspensión de profilaxis frente a neumonia por Pneumocystis carinii en pacientes con tratamiento antirretroviral combinado eficaz. Estudio de 85 casos. Med Clin (Bac) 1999; 113: 89-90.
9. Riera M, Villalonga C, Homar F, Payeras A, Altes J, Salas A et al. Evolución de la supervivencia y de la incidencia de infecciones oportunistas y tumores en los pacientes con SIDA (1986-1997) [resumen 6-10]. Resumen de VIII Congreso Sociedad Española de Enfermedades Infecciosas y microbiología Clínica. Palma de Mallorca, mayo de 1998.
10. Rodríguez-Rosado R, Soriano V, Dona C, González-Lahoz J. Opportunistic infections shortly after beginning highly active antirretroviral therapy. Antivir Ther. 1998; 3: 229-231.
11. Estrada V, Roca V, Télles MJ, Peréz-Cecilia E, Velasco M. Herpes zoster reactivation soon after beginning HAART [abstract P294]. Abstracts of the Fourth International Congress on Drug Therapy in HIV infection, Glasgow, Scotland. AIDS 1998; 12 (Supl 4): 90.
12. Ntampakas P, Loch O, Groebel FD, Bogner JR. Upper respiratory infections (URI) in feed patients at different stages- clinical signs, diagnosis and treatment [abstract P274]. Abstracts of the Fourth International Congress on Drug Therapy in HIV infection, Glasgow, Scotland. AIDS 1998; 12 (Supl 4): 85.
13. Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos Al, Katzenstein T et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130: 570-577.
14. Lundgren JD, Miller V, Blaxhult A, Churchill D, Parkin J, Chiesi A et al, for the EuroSIDA study group CD4 Count and viral load changes in response to ≥ 3 drugs therapy in EuroSIDA: association with clinical disease progression [abstract P253]. Abstracts of the Fourth International congress on drug Therapy in HIV- infection, Glasgow, Scotland AIDS 1998; 12 (supl 4): 60.
15. Mellors JW, Muñoz A, Giorgi JV Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Anr Intern Med 1997; 126: 946-954.
16. Romeu J, Balagué M, Ruiz L, Marfil S, Puig T, Arno A et al. Valor de a carga viral del VIH-1 y de los linfocitos CD4+ como determinantes de la progresión a sida y de la supervivencia. Med Clin (Barc) 1998; 110: 761-767.
17. Yerly S, Perneger T, Hirschel B. HIV viraemia influences survival in HIV infected patients. [Abstract We.B413] IX International conference on AIDS. Vancouver, julio de 1996.
18. Lepri A C, Katzenstein TL, Ullum H, Phillips AN, Skinhcj I, Gerstoft J et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998; 12: 1639-1643.